Effect of Different Acupuncture Schemes for Postoperative Urinary Retention in Cervical Cancer Patients

February 5, 2026 updated by: Lu Chao

Effect of Acupuncture at Different Combinations of Acupoints for Postoperative Urinary Retention After Radical Hysterectomy of Cervical Cancer: a Retrospective Cohort Study

This is a retrospective cohort study using a paired control design. We will review the patients of PUR after cervical cancer surgery who went to the acupuncture department and the urinary retention department in Zhejiang Cancer Hospital from October 2020 to August 2024, and 73 patients met the screening criteria. All patients provided written informed consent. The purpose of the study is to compare the effect of acupuncture at different combinations of acupoints for postoperative urinary retention (PUR) after radical hysterectomy of cervical cancer. All outcome-measures data were obtained from past medical records. It is an observational study rather than an intervention study. 73 patients met the screening criteria. They will be assigned into two groups according to the treatment scheme of acupoints combination for acupuncture: Group A (37 cases) and Group B (36 cases).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

73

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310022
        • Zhejiang Cancer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients of postoperative urinary retention after radical hysterectomy of cervical cancer

Description

Inclusion Criteria:

  • 18-70 years old
  • Karnofsky Performance Scale (KPS) score > 70
  • met the diagnostic criteria of PUR
  • no history of serious urinary system diseases or urinary retention before the operation
  • had clear cognition and no severe mental diseases
  • had complete medical records and records of residual urine volume data.

Exclusion Criteria:

  • presence of other serious systemic diseases or advanced cachexia
  • obstructive urinary retention caused by urethral stricture, stones, or other diseases
  • receiving other treatments or self-change treatment
  • poor compliance or failure to complete the acupuncture treatments
  • incomplete clinical data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group A
Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally.
Other: Acupuncture
Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks
Other Names:
  • Electroacupuncture
Other: Acupuncture
Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
Other Names:
  • Electroacupuncture
Group B
Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6).
Other: Acupuncture
Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks
Other Names:
  • Electroacupuncture
Other: Acupuncture
Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
Other Names:
  • Electroacupuncture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The change value in residual urine volume
Time Frame: baseline and 2 weeks
Residual urine volume was assessed before the first treatment and after the final treatment by a trained outpatient nurse using a direct measurement method involving catheter insertion for urine drainage and measurement. Calculate the difference value in residual urine volume before and after treatment.
baseline and 2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The patient's abdominal distension sensation by the visual analog scale (VAS) method
Time Frame: baseline and 2 weeks
Patients were asked to mark their level of abdominal distension sensation on the line, with 0 indicating no abdominal distension and 10 indicating extremely severe abdominal distension.
baseline and 2 weeks
The occurrence of urinary tract infections
Time Frame: baseline and 2 weeks
Count the number of urinary tract infections and calculate the incidence rate
baseline and 2 weeks
The total effective rate
Time Frame: 2 weeks
Clinical efficacy was assessed based on the change in residual urine volume before and after treatment. Cured: the residual urine volume was significantly decreased and less than 100 ml after treatment, and the catheter was removed with no recurrence during follow-up; Improved: the residual urine volume remained over 100 ml, but decreased by more than 100 ml compared to before treatment; Unimproved: the residual urine volume did not significantly decreased (less than 100 ml) or worsened. The total effective rate was calculated as the number of cured and improved patients divided by the total number of patients×100%.
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Lu Chao

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Actual)

October 31, 2025

Study Completion (Actual)

October 31, 2025

Study Registration Dates

First Submitted

October 9, 2024

First Submitted That Met QC Criteria

October 10, 2024

First Posted (Actual)

October 15, 2024

Study Record Updates

Last Update Posted (Actual)

February 6, 2026

Last Update Submitted That Met QC Criteria

February 5, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IIT-2024-385

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Urinary Retention (POUR)

Clinical Trials on Acupuncture

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe